Milestone Pharmaceuticals(MIST) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. "Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etrip ...